
Brickell Biotech BBI
Annual report 2023
added 03-15-2024
Brickell Biotech Total Non Current Liabilities 2011-2026 | BBI
Annual Total Non Current Liabilities Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 146 K | 73 K | - | - | - | 359 K | 856 K | 1.29 M | 1.66 M | 1.96 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.96 M | 73 K | 906 K |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Processa Pharmaceuticals
PCSA
|
1.05 M | $ 2.3 | -1.29 % | $ 3.01 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 220.9 | 2.49 % | $ 5 B | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 19.57 | 1.77 % | $ 915 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Phathom Pharmaceuticals
PHAT
|
45.3 M | $ 10.47 | 4.08 % | $ 763 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Pliant Therapeutics
PLRX
|
866 K | $ 1.31 | 2.34 % | $ 80.4 M | ||
|
PMV Pharmaceuticals
PMVP
|
169 M | $ 1.37 | -1.44 % | $ 72 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.33 | 0.76 % | $ 339 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
25.1 M | $ 8.31 | 1.59 % | $ 111 M | ||
|
CRISPR Therapeutics AG
CRSP
|
70.2 M | $ 47.09 | 1.42 % | $ 4.23 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
1.06 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
32 K | $ 3.26 | 4.49 % | $ 251 M | ||
|
Dynavax Technologies Corporation
DVAX
|
218 M | - | - | $ 2.02 B | ||
|
ProQR Therapeutics N.V.
PRQR
|
31.9 M | $ 1.58 | 6.04 % | $ 99.5 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Palatin Technologies
PTN
|
953 K | $ 21.0 | 5.79 % | $ 19.5 M | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Pulmatrix
PULM
|
7.88 M | $ 2.12 | -1.4 % | $ 7.74 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.53 | 5.1 % | $ 868 M | ||
|
Homology Medicines
FIXX
|
45.1 M | - | 0.77 % | $ 53.4 M |